Additionally, the FDA accepted Eisai's Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for ...
“Along with my admiration for blue-and-white porcelain, my passion for textiles and embroidery was passed down to me by my grandmother.” Bringing conceptual elements to needlework, a craft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback